News Archive – SFAtx

YEAR

By admin

In news archive

Posted October 28, 2019

FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company’s novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC).

View Press Release

By admin

In news archive

Posted October 28, 2019

FDA Orphan Drug Designation Granted

The orphan drug designation will provide SFA Therapeutics with significant drug development and tax advantages as well as an expanded period of market exclusivity. Link to Press Release

By admin

In news archive

Posted December 15, 2017

Overview of SFA Therapeutics

SFA Therapeutics’ CEO Dr Ira Spector presents an overview of the company and its platform technology SFA Overview Presentation on YouTube Introduction to SFA Liver Disease and Oncology [...]